Hemophagocytic lymphohistiocytosis in pregnancy evolving towards fulminant hepatitis. (September 2022)

• Record Type: Journal Article
• Authors: Simard, Camille; Tardif, Marie-Lou
• Is Part Of: Obstetric medicine. Volume 15:Number 3(2022)
• Page Start: 208
• Page End: 211
• Publication Date: 2022-09
• Subjects: Hemophagocytic lymphohistiocytosis -- pregnancy; Pregnancy -- Complications -- Periodicals; Obstetrics -- Periodicals; 618.2
• DOI: 10.1177/1753495X21999914
• Languages: English
• ISSNs: 1753-495X

Abstract

Background: Hemophagocytic lymphohistiocytosis is a rare disorder, especially in pregnancy, characterized by excessive immune activation leading to hemophagocytic activity. Case Report: A 34-year-old woman presented at 31 weeks' gestation with fever, cytopenias, hyperferritinemia and fulminant hepatitis. Bone marrow biopsy was non-contributory, and no trigger was identified. Liver biopsy confirmed the diagnosis of hemophagocytic lymphohistiocytosis, and she received dexamethasone and etoposide, which was changed to anakinra to allow breastfeeding. Prompt diagnosis and treatment of hemophagocytic lymphohistiocytosis is crucial to the survival of pregnant women, but no consensus exists regarding the most appropriate therapy during pregnancy. Conclusion: Hemophagocytic lymphohistiocytosis is life-threatening and associated with significant morbidity and mortality. Important treatment considerations in pregnancy include maternal health, fetal prematurity and treatment toxicity. Anakinra has been successfully used in pregnancy and provides a promising alternative.